- Hemophilia A
- Hemophilia B
Hemophilia is a rare blood disorder, in which blood doesnt clot normally due to lack of sufficient clotting factors. Hemophilia A and B both are inherited diseases. Hemophilia A, B caused due to deficiency of clotting factor VIII,IX respectively. Hemophilia causes by genetic mutation. The mutations that involve genes that code the clotting factors.
Hereditary hemophilia can be easily diagnosed during the pregnancy if the fetus is suffering from hemophilia. In absence of hereditary hemophilia, disease may be due to the spontaneous mutations in gene. Hemophilia in both children and adults, blood test to determine the clotting factor may be preferred. Treatment depends on the type of hemophilia.
Key Development:
- In November 2017, Roche (Genentech)announced positive results for its PhaseIII trial (HAVEN III) in patients withhemophilia A without inhibitors. Theonce?weekly Hemlibra therapy reportedsuperiority in reducing treated bleeds tofactor VIII prophylaxis in an intra?patientcomparison.
- In April 2017, Catalyst Biosciences announced it had received approval from the KoreanMinistry of Food and safety to beginhuman clinical trials for its newinvestigational drug CB2679dISU304 for treatment of hemophilia B.
Hemophilia Pipeline Drugs Assessment Dynamics
Hemophilia Pipeline Drugs Assessment report studies the various therapeutics under clinical development for hemophiliatreatment along with targets for various drug candidate. The report provides plethora of information on trail phases, companies involved in the hemophilia pipeline drugsdevelopment. This report studies the dynamics of the Hemophilia Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on hemophilia pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Hemophilia Pipeline Drugs Assessment Segmentation
By Type
By Trial Phase
- Preclinical Studies
- Phase-I
- Phase-II
- Phase-III
- Phase-IV
By Mechanism
- Inhibitors
- Factor Concentrates
- Gene Therapy
- Non-Factor Concentrates
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Hemophilia Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Hemophilia Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Hemophilia Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Trial Phase |
| 2.2.3.Mechanism |
| 3. Global Hemophilia Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Hemophilia Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Hemophilia Pipeline Drugs Assessment Market By Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Hemophilia A |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Hemophilia B |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Hemophilia Pipeline Drugs Assessment Market By Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Preclinical Studies |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Phase-I |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Phase-II |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Phase-III |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Phase-IV |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Hemophilia Pipeline Drugs Assessment Market By Mechanism, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Inhibitors |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Factor Concentrates |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Gene Therapy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Non-Factor Concentrates |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Competition Landscape |
| 8.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 8.2.1.Pfizer Inc. (U.S.) |
| 8.2.2.Hoffmann-La Roche AG (Switzerland) |
| 8.2.3.Novo Nordisk A/S (Denmark) |
| 8.2.4.Shire Plc. (Republic of Ireland) |
| 8.2.5.Alnylam Pharmaceuticals (U.S.) |
| 8.2.6.OPKO Health (U.S.) |
| 9. Research Methodology |
| 10. Appendix and Abbreviations |
- Pfizer Inc. (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- Novo Nordisk A/S (Denmark)
- Shire Plc. (Republic of Ireland)
- Alnylam Pharmaceuticals (U.S.)
- OPKO Health (U.S.)